Stock·NYSE·Healthcare
Abbott Laboratories (ABT)
- Market cap
- $183.77B
- P/E
- 39.51
- Dividend yield
- 2.37%
- Street target
- $120.00median of 28 analysts
- 52-week range
- $81.97 $132.03
ABT stock forecast today
Where ABT stands today, and what CleaRank Financial AI makes of it.
ABT at a glance
Abbott Laboratories (ABT): Buy, 64/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($104.34 and $101.69).
- Earnings ABT beat estimates in 3 of the 7 reports in our data, yet fell the next day after 1 of those beats.
- Insiders Insiders sold $48.3M and bought $4.4M over the last 18 months.
- Valuation P/E of 39.5 against 31.9 for the Healthcare sector: a premium to peers (+24%).
Figures as of October 30, 2026.
CleaRank Financial AI
ABT, or Abbott Laboratories, carries a CleaRank rating of Buy and a model score of 64/100.
Analysts lift that score the most: 24 of 28 rate the stock a buy, with the median target 13.0% above the price. Valuation pulls hardest against it, since the P/E of 39.51 is 23.9% above the sector median (a premium to peers) and the P/S of 3.81 is 12.1% above the sector median. Trend is up, with the price 1.78% above its 50-day average of $104.34 and 4.43% above its 200-day average of $101.69. Across the last year, though, the price declined 14.82%.
Only on CleaRank
Figures we compute ourselves from ABT's own price, earnings and insider-filing history. Tap one to see it in context.
ABT stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price above its 50-day average ›
The price of $106.20 is 1.8% above the 50-day simple moving average of $104.34.Price above its 200-day average ›
The price is 4.4% above the 200-day simple moving average of $101.69.50-day average above the 200-day ›
The 50-day average ($104.34) is 2.6% above the 200-day average ($101.69), the arrangement of a rising longer-term trend.In the lower half of its 52-week range ›
The price sits at 48% of its 52-week range, between $81.97 and $132.03.
ABT share price
Pick a period: each tab shows how far ABT has moved over it, to the last close.
Today's trading
Where ABT sits inside today's range and its 52-week range.
ABT fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
2/5P/E above the sector median ›
The trailing P/E of 39.51 is 23.9% above the Healthcare median of 31.9.P/S above the sector median ›
The price-to-sales ratio of 3.81 is 12.2% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $4.7B on revenue of $48.2B, a net margin of 9.7%.Missed estimates in most recent reports ›
ABT beat the EPS estimate in 3 of the 7 reports in our data.Pays a dividend ›
The trailing dividend yield is 2.37%, or $2.52 a share a year.
Key statistics
The headline figures for ABT.
As of October 30, 2026, ABT trades at $106.20, with a market value of $183.77B, a P/E ratio of 39.51 and a dividend yield of 2.37%.
What the numbers say
CleaRank Financial AI's reading of ABT's valuation, growth and risks.
ABT's trailing P/E is 39.51, which puts it 23.9% above the Healthcare median of 31.9. The peer comparison on this page gives that P/E verdict as a premium to peers. On sales, the P/S is 3.81, 12.1% above the sector median of 3.4. Abbott Laboratories (ABT) has a market value of $183.8B, and its trailing earnings come to $2.69 per share.
Profitability shows a net margin of 9.75% and an operating margin of 11.34%. It reports a return on equity of 12.36%, above the sector median of 7.3%. It also reports debt-to-equity of 0.63 and a trailing dividend yield of 2.37% ($2.52 a share a year).
In its last earnings report, on October 21, 2026, ABT posted $1.42 a share against a $1.42 estimate, in line with the estimate. The stock still rose 1.99% in the next session.
ABT has beaten the EPS estimate in 3 of the 7 reports in our data, yet the shares still declined in the first session after 1 of those 3 beats. For this fiscal year, analysts' average EPS estimate is $5.52, a rise of 7.2%. Next year's estimate is $5.95, which implies growth of 7.8%.
Because the P/E of 39.51 sits 23.9% above the sector median and is a premium to peers, there is less room for error in the valuation. ABT's average daily move is 1.42%, and its beta against the S&P 500 is 0.58. The stock is 19.56% below its 52-week high of $132.03.
ABT against the Healthcare sector
How ABT compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: ABT trades at a significant premium to sector peers (+24%), suggesting market expectations for superior growth or market position.
Return vs XLV: Since May 20, 2025, ABT has lost 21.5% against a gain of 37.3% for XLV.
Performance against XLV
ABT and the Healthcare sector fund over the same days.
Revenue and earnings
How much ABT sells, and how much of it becomes profit.
The quarterly bars end with Q1 '26 (the quarter to March 31, 2026); ABT reported again on October 21, 2026, and that quarter is not in our statement data yet. The 12-month figures come from the statistics feed and may include it.
Revenue growth: Revenue grew 5.7% in FY2025 to $44.3B, from $42.0B a year earlier.
Profit margin: The net margin was 14.7% in FY2025, down from 31.9% the year before.
Profitable: ABT earned $6.5B in FY2025.
Earnings reality check
Did ABT beat what analysts expected, and how did the stock react?
Earnings record: ABT beat the analyst estimate in 3 of the 7 reports in our data.
Market reaction: The stock fell in the first session after 1 of those 3 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Oct 21, 2026after close | $1.42 | $1.42 | +0.00% | +1.99% | +2.12% |
| Jul 16, 2026after close | $1.28 | $1.31 | +2.34% | +1.87% | +1.94% |
| Jan 22, 2026after close | $1.49 | $1.50 | +0.67% | -1.10% | -2.32% |
| Oct 15, 2025after close | $1.30 | $1.30 | +0.00% | -1.41% | -1.16% |
| Jul 17, 2025after close | $1.26 | $1.26 | +0.00% | +2.62% | +4.26% |
| Apr 16, 2025after close | $1.07 | $1.09 | +1.87% | +0.99% | -0.25% |
| Jan 22, 2025after close | $1.34 | $1.34 | +0.00% | +4.62% | +8.56% |
As of October 30, 2026, ABT has beaten the analyst EPS estimate in 3 of the 7 reports in our data and fell in the first trading session after 1 of those beats; its latest report, on October 21, 2026, came in 0.00% above the estimate and the stock moved +1.99% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
ABT AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 59.5, in neutral territory.RSI above 50 ›
An RSI of 59.5 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of ABT
The score, the reasoning behind it, and what could move the price next.
Abbott Laboratories (ABT) shows an uptrend in its averages: the price sits above both of them. At $106.20, the stock is 1.78% above its 50-day average of $104.34 and 4.43% above its 200-day average of $101.69. Within its 52-week range, between $81.97 and $132.03, the price stands at 48%.
Recent gains sit against a weaker longer record: the price rose 7.46% over the past month, rose 0.47% over the past three months and fell 14.82% over the past year. On momentum, the 14-day RSI reads 59.5, in the neutral zone, with the MACD line positive.
Rating reaffirmed ›
Wells Fargo kept its Overweight rating on October 23, 2026.
Source: Analyst action, Wells Fargo, October 23, 2026
Earnings in line ›
The October 21, 2026 report came in line with the EPS estimate, and the share price rose 1.99% in the first session after it.
Source: Earnings report, October 21, 2026
- Two levels matter most: the 52-week high at $132.03 above the price, and the 50-day SMA at $104.34 below it.
- The 14-day RSI is 59.5, which is neutral, and the MACD line is positive. Readings above 70 or below 30 would point to stretched momentum.
- The share price rose 1.99% in the first session after the October 21, 2026 report. ABT has beaten estimates in 3 of the 7 reports in our data.
ABT trades above its 50-day and 200-day moving averages ($104.34 and $101.69), which is what makes the trend up; losing the 50-day would be the first warning. The nearest level under the price is the 50-day SMA at $104.34.
ABT's next overhead level is the 52-week high at $132.03. Its 14-day RSI of 59.5 keeps the stock in the neutral zone, which runs from 40 to 60.
Technical indicators
Momentum and trend for ABT, from its daily closes.
As of October 30, 2026, with ABT at $106.20, its 14-day RSI is 59.5 (neutral territory), its 50-day simple moving average is $104.34 and its 200-day is $101.69.
Calculated by CleaRank on daily closes as of October 30, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What ABT moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 30, 2026, ABT's 1-year correlation of daily returns is +0.11 with S&P 500 (SPY), -0.03 with Nasdaq 100 (QQQ), -0.07 with Bitcoin (BTC) and +0.03 with gold (XAU).
ABT price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
24 of 28 analysts rate it a buy or strong buy, 4 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $120.00 is 13.0% above the price.More buy ratings than three months ago ›
24 of 28 rate it a buy now, against 20 of 27 three months ago.
ABT Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 23, 2026 | Wells Fargo | Maintains | Overweight |
| Oct 22, 2026 | Citigroup | Maintains | Buy |
| Oct 22, 2026 | RBC Capital | Maintains | Outperform |
| Oct 22, 2026 | Wells Fargo | Maintains | Overweight |
| Oct 22, 2026 | JP Morgan | Maintains | Overweight |
| Oct 22, 2026 | TD Cowen | Maintains | Buy |
As of October 30, 2026, 28 Wall Street analysts cover ABT: 24 rate it a buy or strong buy, 4 a hold and 0 a sell or strong sell. Their 12-month price targets range from $100.00 to $130.00. The median ABT price target is $120.00, 13.0% above the price of $106.20.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
ABT trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
ABT trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from ABT's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much ABT tends to move, against the market and on its own.
ABT price history and drawdowns
ABT's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 1.42% on an average day (30-day standard deviation of daily returns).Not yet recovered from its worst fall ›
The worst fall was 37.5%, from March 2025 to May 2026; the price is still 19.8% below that peak.Most 1-year holds ended higher ›
72% of 1-year holding periods in the last 10 years ended with a gain.Trailed the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $32,634, against $41,607 in the S&P 500 (SPY).
ABT Drawdowns & Recovery
As of October 30, 2026, ABT's worst peak-to-trough fall over the last 10 years with dividends reinvested was -37.5% (March 2025 to May 2026); it is still 19.8% below that peak, and 72% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into ABT in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: ABT trailed the S&P 500 over this period: $32,634 against $41,607.
A $10,000 investment in ABT in October 2016 would be worth about $32,634 today with dividends reinvested, compared with about $41,607 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to ABT, and which have not.
Strongest month, July: an average of +4.77%, up in 9 of 10 years.
Weakest month, March: an average of -3.04%, up in 1 of 10 years.
This month, October: has averaged -0.41%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, ABT's strongest calendar month has been July (average +4.77%, up in 9 of 10 years) and its weakest March (average -3.04%, up in 1 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
ABT stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in ABT, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in ABT today could grow to about $13,560 by 2030 in the base case, with a 90th-percentile outcome near $25,100 and a 10th-percentile outcome around $7,325. The simulation models price only; at today's 2.37% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
ABT Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $144 for ABT by 2030 in the base case, from $106 today (1.4x over 4 years). The 10th-percentile path ends near $77.80. These are outcomes of a Monte Carlo simulation run on ABT's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $84.23 | $115 | $156 | |
| 2028 | $80.01 | $124 | $191 | |
| 2029 | $78.29 | $133 | $227 | |
| 2030 | $77.80 | $144 | $267 |
Method: a lognormal simulation of ABT's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
ABT insider trading
What the people running the company have bought and sold.
ABT insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: Insiders bought $4.4M on the open market and sold $48.3M.
As of October 30, 2026, ABT insiders reported 11 open-market sales worth $48.3M and 5 open-market purchases worth $4.4M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 2, 2026 | John A. Mccoy Jr
Officer
|
Sell | 27 | $3.0K |
| Aug 25, 2026 | Robert B. Ford
Chief Executive Officer
|
Sell | 398.8K | $46.2M |
| Aug 25, 2026 | Robert B. Ford
Chief Executive Officer
|
Option | 398.8K | $21.5M |
| Aug 11, 2026 | Louis H Morrone
Officer
|
Sell | 5.9K | $642.5K |
| May 7, 2026 | John G. Stratton
Director
|
Buy | 2.0K | $173.6K |
| Apr 27, 2026 | Daniel J Starks
Director
|
Buy | 10.0K | $926.5K |
| Apr 24, 2026 | Nita Ahuja, M.D.
Director
|
Grant | 2.3K | - |
| Apr 24, 2026 | Claire Fontenot Babineaux
Director
|
Grant | 2.3K | - |
| Apr 24, 2026 | Sally E Blount
Director
|
Grant | 2.3K | - |
| Apr 24, 2026 | Kevin T Conroy
Director
|
Grant | 2.3K | - |
| Apr 24, 2026 | Patricia Paola Gonzalez
Director
|
Grant | 2.3K | - |
| Apr 24, 2026 | Michelle A Kumbier
Director
|
Grant | 2.3K | - |
| Apr 24, 2026 | Darren W Mcdew
Director
|
Grant | 2.3K | - |
| Apr 24, 2026 | Nancy Mckinstry
Director
|
Grant | 2.3K | - |
| Apr 24, 2026 | Grady Michael G O
Director
|
Grant | 2.3K | - |
| Apr 24, 2026 | Michael F Roman
Director
|
Grant | 2.3K | - |
| Apr 24, 2026 | Daniel J Starks
Director
|
Grant | 2.3K | - |
| Apr 24, 2026 | John G. Stratton
Director
|
Grant | 2.3K | - |
| Apr 23, 2026 | Philip P Boudreau
Chief Financial Officer
|
Buy | 2.2K | $201.3K |
| Mar 23, 2026 | Jacob A Orville
Officer
|
Grant | 13.3K | - |
| Mar 2, 2026 | Louis H Morrone
Officer
|
Sell | 1.1K | $132.2K |
| Mar 2, 2026 | Daniel Gesua Sive Salvadori
Officer
|
Sell | 885 | $102.3K |
| Mar 2, 2026 | Eric Shroff
Officer
|
Sell | 709 | $81.9K |
| Mar 2, 2026 | Mary K Moreland
Officer
|
Sell | 613 | $70.9K |
| Mar 2, 2026 | John A. Mccoy Jr
Officer
|
Sell | 585 | $67.6K |
| Mar 2, 2026 | Elizabeth C Cushman
General Counsel
|
Sell | 263 | $30.4K |
| Feb 24, 2026 | Philip P Boudreau
Chief Financial Officer
|
Grant | 28.0K | - |
| Feb 24, 2026 | Elizabeth C Cushman
General Counsel
|
Grant | 15.0K | - |
| Feb 24, 2026 | Lisa D Earnhardt
Officer
|
Grant | 27.1K | - |
| Feb 24, 2026 | Robert B. Ford
Chief Executive Officer
|
Grant | 83.5K | - |
| Feb 24, 2026 | John A. Mccoy Jr
Officer
|
Grant | 5.4K | - |
| Feb 24, 2026 | Mary K Moreland
Officer
|
Grant | 14.0K | - |
| Feb 24, 2026 | Louis H Morrone
Officer
|
Grant | 15.4K | - |
| Feb 24, 2026 | Daniel Gesua Sive Salvadori
Officer
|
Grant | 21.6K | - |
| Feb 24, 2026 | Christopher J Scoggins
Officer
|
Grant | 18.5K | - |
| Feb 24, 2026 | Eric Shroff
Officer
|
Grant | 10.9K | - |
| Feb 4, 2026 | Daniel J Starks
Director
|
Buy | 10.0K | $1.1M |
| Jan 23, 2026 | Robert B. Ford
Chief Executive Officer
|
Buy | 18.8K | $2.0M |
| Dec 11, 2025 | Daniel Gesua Sive Salvadori
Officer
|
Grant | 1.5K | $189.4K |
| Nov 25, 2025 | Eric Shroff
Officer
|
Sell | 1.6K | $203.0K |
| Aug 8, 2025 | Philip P Boudreau
Chief Financial Officer
|
Sell | 5.6K | $746.8K |
| Jun 27, 2025 | Elizabeth C Cushman
General Counsel
|
Grant | 3.8K | - |
Source: TwelveData, from SEC Form 4 filings
ABT stock forecast: questions people ask
Answered from the figures on this page, as of October 30, 2026.